SAVA, a pioneering startup at the intersection of health technology and innovation, emerges from five years of stealth to announce a significant milestone: securing over €7.4 million in a Seed funding round led by Balderton Capital and Exor Ventures.
Founded by Renato Circi and Rafael Michali, bioengineers hailing from Imperial College London, SAVA introduces a game-changing microsensing device designed to detect molecules in the interstitial fluid just beneath the skin. This revolutionary technology is embedded within a smart, connected wearable patch that seamlessly transmits real-time health data directly to a user’s mobile device.
SAVA’s flagship microsensor initially targets glucose monitoring for individuals with diabetes, a condition projected to affect over 783 million adults globally by 2045. With diabetes care increasingly relying on accurate glucose monitoring technologies like Continuous Glucose Monitors (CGMs), SAVA’s innovation promises pain-free, affordable insights crucial for managing this chronic disease. The NHS in the UK alone has committed to providing CGMs to all Type I diabetes patients by 2025, highlighting the critical need and expansive market potential.
Recently granted approval by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for clinical trials, SAVA is set to validate its breakthrough technology on a larger scale. This rigorous validation process ensures both the safety and performance of the microsensor, paving the way for upcoming clinical investigations in collaboration with leading researchers from the Universities of Oxford and Cambridge.
Beyond diabetes management, SAVA’s modular design aims to revolutionize healthcare by enabling simultaneous monitoring of multiple molecules. This capability opens doors to monitoring chronic conditions, enhancing wellbeing applications, improving drug adherence, and personalizing therapies, marking a paradigm shift towards preventative healthcare.
With total funding now reaching $13 million from prominent VC firms, angel investors, and government entities like the European Union and UK Government through Innovate UK, SAVA plans to expand its team, enhance manufacturing capabilities, and further demonstrate the clinical efficacy of its platform.
Renato Circi, co-founder of SAVA, expressed enthusiasm about the funding round, stating, “At SAVA, we’re pioneering a new era in health monitoring by making advanced technology accessible to all. This capital infusion accelerates our mission to transform healthcare into a preventative, personalized, and painless experience.”
Co-founder Rafael Michali added, “SAVA is dedicated to empowering individuals to proactively manage their health through effortless access to real-time insights. Our goal is to redefine healthcare systems worldwide.”
James Wise, Partner at Balderton Capital, underscored the potential impact of SAVA’s technology, describing it as potentially transformative in chronic disease management and preventative care. He praised Renato and Rafael’s vision and expertise in driving innovation in healthcare.
Noam Ohana and Ileana Pirozzi of Exor Ventures emphasized SAVA’s unique approach and technological prowess, highlighting its potential to reshape healthcare infrastructure and inspire further innovation in biosensing.
SAVA’s journey exemplifies a commitment to advancing healthcare through groundbreaking technology, promising a future where health monitoring is not just reactive but proactive, empowering individuals and transforming global healthcare standards. Source: Eu-startups and SAVA
